Conditions: Episodic Migraine
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 76
Healthy volunteers: no

Brief summary:
Evidence-based medicine depends on distinguishing between pharmacological effects and placebo effects in randomized controlled trials (RCT). This proposal seeks to rigorously investigate fundamental questions concerning pharmacological effects, placebo effects and their interactions. Relief of symptoms of acute migraine will be the test condition for this scientific experiment because of migraine's evident clinical significance and the possibility of using participants as their own control during sequential acute migraine attacks. Our overall goal is to elucidate how the pharmacological effects of 100 mg rizatriptan (an FDA-proven effective medication for acute migraine) and the effects of placebo treatment can be modified by varied knowledge and/or expectation ("contextual") conditions. Such knowledge has the possibility to suggest potentially more efficient methodologies to test new medications that can be used to augment and enhance the apparatus of the RCT.

General Aim: To elucidate and clarify what is a pharmacological effect and what is a placebo effect, how such effects vary in different knowledge/expectations contexts, and mutually constitute one another and interact.

General Hypothesis: The measured pharmacological effect of an effective medication (rizatriptan) and the measured effect of placebo treatment are determined significantly by different knowledge/expectations contexts.

Detailed description:

Arms:
arm 1: Maxalt administration at onset of migraine arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None

Interventions: intervention 1: Maxalt intervention 2: placebo pill intervention 3: placebo pills
Intervention descriptions: intervention 1: anti-migraine drug intervention 2: placebo pills intervention 3: placebo pills

Protocol document: